ReShape Lifesciences Presents Data On Its Proprietary Diabetes Bloc-Stim Neuromodulation Device At The ASMBS 2023 Annual Meeting
Portfolio Pulse from Happy Mohamed
ReShape Lifesciences Inc. (NASDAQ:RSLS) presented data on its proprietary Diabetes Bloc-Stim Neuromodulation (DBSN) device at the ASMBS 2023 Annual Meeting. The device selectively modulates vagal block and stimulation to the liver and pancreas to manage blood glucose. The company's CEO, Paul F. Hickey, stated that the DBSN device has the potential to deliver personalized therapy by adjusting insulin production, thus potentially reducing dependence on medication.
June 28, 2023 | 12:38 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ReShape Lifesciences' DBSN device shows promise in managing blood glucose, potentially reducing dependence on medication. This could have a positive impact on the company's stock as it indicates progress in their product development.
The news about the promising data on ReShape Lifesciences' DBSN device is directly related to the company and its product development. If the device proves to be effective in managing blood glucose and reducing dependence on medication, it could lead to increased demand for the product, potentially boosting the company's revenues and positively impacting its stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100